A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs AZD 5004 (Primary) ; Semaglutide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SOLSTICE
- Sponsors AstraZeneca
- 21 Oct 2024 Planned End Date changed from 23 Dec 2025 to 6 Jan 2026.
- 21 Oct 2024 Planned primary completion date changed from 23 Dec 2025 to 6 Jan 2026.
- 21 Oct 2024 Status changed from not yet recruiting to recruiting.